Mancini Anthony 4

What Happened
Anthony Mancini, Chief Global Commercialization Officer of Revolution Medicines (RVMD), disposed of 4,615 shares on June 16, 2026 in an open-market sale. The shares were sold at a weighted average price of $156.12 per share for total proceeds of approximately $720,490. The filing indicates the sale followed the vesting of restricted stock units and was executed to cover applicable withholding taxes.

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-18 (timely filing).
• Transaction type/code: Sale (S); amount: 4,615 shares; weighted average price: $156.12; total ≈ $720,490.
• Price details: trade prices ranged from $156.1105 to $156.8250 across multiple trades; the reported price is the weighted average.
• Reason/footnote: Sale was an automatic sell-to-cover to cover tax withholding after RSU vesting (F1).
• Holdings notes: Filing references 43,700 Restricted Stock Units and 190 shares from the issuer’s Employee Stock Purchase Plan (ESPP); the filing text provided here does not state the total shares owned after the transaction.
• Reporting person role: Chief Global Commercialization Officer (remark).
• The reporting person offered to provide full trade-by-trade details upon request (per F2).

Context
A sell-to-cover is a routine administrative sale executed to pay taxes when restricted stock units vest; it does not necessarily indicate a decision to liquidate additional holdings. The filing is informational and appears timely under Form 4 reporting rules.